Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No Benefit With Rituximab After First CR in DLBCL

Key clinical point: Rituximab maintenance did not improve disease-free or overall survival of diffuse large B-cell lymphoma in first remission.

Major finding: The 5-year disease-free survival rates were 79% with rituximab maintenance versus 74% with observation.

Study details: An analysis of second randomization from a phase 3 trial comparing rituximab maintenance with observation in 380 patients with diffuse large B-cell lymphoma in first remission after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Disclosures: The study was sponsored by HOVON, the HematoOncology Foundation for Adults in the Netherlands, with additional support from Roche. Dr. Lugtenburg reported consultancy for and research funding from Roche and others. Dr. Trnený reported advisory board activity, research support, and honoraria from Roche and others.

Citation:

Lugtenburg PJ et al. EHA 2019, Abstract S1559.